Novo Nordisk, the global leader in diabetes care, has launched Ryzodeg for patients with type 2 diabetes in India. Ryzodeg is a combination of two distinct insulin analogues. It contains insulin degludec and insulin aspart in the ratio of 70 per cent and 30 per cent, making it the first combination of a basal insulin with an ultra-long duration of action and a well-established mealtime insulin in one pen.

The company stated that patients administering Ryzodeg will have lower risk of hypoglycaemia versus biphasic insulin aspart 30.  The combination product requires fewer daily injections than administering basal and mealtime insulin in separate injections.

People with diabetes currently using basal-bolus regimens may need to take up to four daily injections, which can be inconvenient and stressful. Ryzodegprovides successful glycaemic control, fewer injections and reduced rates of hypoglycaemia compared to basal-bolus regimens.

According to Mads Bo Larsen, Corporate Vice President, Business Area Africa, Gulf & India, Novo Nordisk, “India has close to 65.1 million people with diabetes standing second in the world map. We are focused at providing quality medications that will help health care professionals to meet the demands and challenges of diabetes in India. We are extremely pleased to have introduced Ryzodegre in forcing our commitment to provide best of healthcare solutions for the use of doctors in India.”

“We are always been striving to develop products that address key challenges faced by people with diabetes and physicians. Ryzodeg builds on this heritage as it is an innovative product that will give the health care professional a better way to manage the condition. In a country like India where diabetes has become one of the biggest healthcare challenges, it is critical that product innovations are aimed at assisting physicians to  provide better and effective treatment options,” said Melvin Oscar D’souza, managing director, Novo Nordisk India.